Literature DB >> 19412586

Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005).

T M Berger1, C Aebi, A Duppenthaler, M Stocker.   

Abstract

OBJECTIVES: Respiratory syncytial virus (RSV) infections are a leading cause of hospital admissions in small children. A substantial proportion of these patients require medical and nursing care, which can only be provided in intermediate (IMC) or intensive care units (ICU). This article reports on all children aged < 3 years who required admission to IMC and/or ICU between October 1, 2001 and September 30, 2005 in Switzerland. PATIENTS AND METHODS: We prospectively collected data on all children aged < 3 years who were admitted to an IMC or ICU for an RSV-related illness. Using a detailed questionnaire, we collected information on risk factors, therapy requirements, length of stay in the IMC/ICU and hospital, and outcome.
RESULTS: Of the 577 cases reported during the study period, 90 were excluded because the patients did not fulfill the inclusion criteria; data were incomplete in another 25 cases (5%). Therefore, a total of 462 verified cases were eligible for analysis. At the time of hospital admission, only 31 patients (11%) were older than 12 months. Since RSV infection was not the main reason for IMC/ICU admission in 52% of these patients, we chose to exclude this subgroup from further analyses. Among the 431 infants aged < 12 months, the majority (77%) were former near term or full term (NT/FT) infants with a gestational age > or = 35 weeks without additional risk factors who were hospitalized at a median age of 1.5 months. Gestational age (GA) < 32 weeks, moderate to severe bronchopulmonary dysplasia (BPD), and congenital heart disease (CHD) were all associated with a significant risk increase for IMC/ICU admission (relative risk 14, 56, and 10, for GA < or = 32 weeks, BPD, and CHD, respectively). Compared with NT/FT infants, high-risk infants were hospitalized at an older age (except for infants with CHD), required more invasive and longer respiratory support, and had longer stays in the IMC/ICU and hospital.
CONCLUSIONS: In Switzerland, RSV infections lead to the IMC/ICU admission of approximately 1%-2% of each annual birth cohort. Although prematurity, BPD, and CHD are significant risk factors, non-pharmacological preventive strategies should not be restricted to these high-risk patients but also target young NT/FT infants since they constitute 77% of infants requiring IMC/ICU admission.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19412586     DOI: 10.1007/s15010-008-8130-z

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  44 in total

Review 1.  Antibiotics for bronchiolitis in children.

Authors:  G K P Spurling; K Fonseka; J Doust; C Del Mar
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Authors:  Mark J C Nuijten; Wolfgang Wittenberg; Maximilian Lebmeier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  [Recommendations for the prevention of respiratory syncytial virus infection].

Authors:  J Figueras Aloy; J Quero; E Doménech; M C López Herrera; I Izquierdo; A Losada; J Perapch; M Sánchez-Luna
Journal:  An Pediatr (Barc)       Date:  2005-10       Impact factor: 1.500

Review 4.  Bronchodilators for bronchiolitis.

Authors:  A M Gadomski; A L Bhasale
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

5.  Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

Authors:  Carole A Reeve; John S Whitehall; Petra G Buettner; Robert Norton; David M Reeve; Fleur Francis
Journal:  J Paediatr Child Health       Date:  2006-05       Impact factor: 1.954

6.  Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.

Authors:  L Navér; M Eriksson; U Ewald; A Linde; M Lindroth; J Schollin
Journal:  Acta Paediatr       Date:  2004-11       Impact factor: 2.299

Review 7.  Palivizumab for preterm infants. Is it worth it?

Authors:  N D Embleton; C Harkensee; M C Mckean
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-07       Impact factor: 5.747

Review 8.  Epinephrine for bronchiolitis.

Authors:  L Hartling; N Wiebe; K Russell; H Patel; T P Klassen
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database.

Authors:  Arne Simon; Roland A Ammann; Anja Wilkesmann; Anna M Eis-Hübinger; Oliver Schildgen; Edda Weimann; Hans U Peltner; Peter Seiffert; Angela Süss-Grafeo; Jessie R Groothuis; Johannes Liese; Ralf Pallacks; Andreas Müller
Journal:  Eur J Pediatr       Date:  2007-02-16       Impact factor: 3.183

10.  Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics.

Authors:  Giovanni A Rossi; Maria Cristina Medici; Maria Cristina Arcangeletti; Marcello Lanari; Rocco Merolla; Umberto Di Luzio Paparatti; Michela Silvestri; Angela Pistorio; Carlo Chezzi
Journal:  Eur J Pediatr       Date:  2007-02-17       Impact factor: 3.183

View more
  24 in total

1.  Pattern of Viral Infections among Infants and Children Admitted to the Paediatric Intensive Care Unit at Sultan Qaboos University Hospital, Oman.

Authors:  Anas-Alwogud A Abdelmogheth; Alddai M A Al-Nair; Abdullah A S Balkhair; Akram M Mahmoud; Mohamed El-Naggari
Journal:  Sultan Qaboos Univ Med J       Date:  2014-10-14

2.  Decreased microRNA-140-5p contributes to respiratory syncytial virus disease through targeting Toll-like receptor 4.

Authors:  Yun Zhang; Lingyun Shao
Journal:  Exp Ther Med       Date:  2018-06-08       Impact factor: 2.447

Review 3.  Host and Viral Determinants of Respiratory Syncytial Virus-induced Airway Mucus.

Authors:  Matthew T Stier; R Stokes Peebles
Journal:  Ann Am Thorac Soc       Date:  2018-11

4.  The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.

Authors:  Michelle L Butt; Amanda Symington; Marianne Janes; Louann Elliott; Susan Steele; Bosco A Paes
Journal:  Eur J Pediatr       Date:  2010-12-22       Impact factor: 3.183

5.  Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis.

Authors:  Cesar Mella; M Carmen Suarez-Arrabal; Santiago Lopez; Julie Stephens; Soledad Fernandez; Mark W Hall; Octavio Ramilo; Asuncion Mejias
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

6.  Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.

Authors:  Hale Çitlenbik; Emel Ulusoy; Anıl Er; Aykut Çağlar; Fatma Akgül; Tuncay Küme; Durgül Yılmaz; Murat Duman
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-09-17       Impact factor: 1.349

Review 7.  Prematurity and the burden of influenza and respiratory syncytial virus disease.

Authors:  Bernhard Resch; Stefan Kurath-Koller; Monika Eibisberger; Werner Zenz
Journal:  World J Pediatr       Date:  2015-11-19       Impact factor: 2.764

8.  Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study.

Authors:  J-B Gouyon; J-C Rozé; C Guillermet-Fromentin; I Glorieux; L Adamon; M DI Maio; T Miloradovich; D Anghelescu; D Pinquier; B Escande; C Elleau
Journal:  Epidemiol Infect       Date:  2012-06-15       Impact factor: 4.434

9.  Managing the morbidity associated with respiratory viral infections in children with congenital heart disease.

Authors:  Joseph M Geskey; Stephen E Cyran
Journal:  Int J Pediatr       Date:  2012-02-29

10.  Impact on parents of bronchiolitis hospitalization of full-term, preterm and congenital heart disease infants.

Authors:  Alexandre Lapillonne; Antoine Regnault; Véronique Gournay; Jean-Bernard Gouyon; Hélène Gilet; Daniela Anghelescu; Tatiana Miloradovich; Benoit Arnould; Guy Moriette
Journal:  BMC Pediatr       Date:  2012-10-31       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.